Nagendran Sukumar insider trades
Nagendran Sukumar has filed 20 Form 4s with the SEC that we hold, for Taysha Gene Therapies, Inc. (TSHA) (President and Head of R&D, Director) and Solid Biosciences Inc. (SLDB) (Director). Across all of them we count 2 purchases worth $83.5K and 9 sales worth $6.1M reported on Form 4. In the last 12 months: 0 purchases ($0) and 7 sales ($5.3M). The largest single trade was a sale of 200,000 shares of Taysha Gene Therapies, Inc. worth $1.2M, dated 2026-07-10. The first filing on our record is dated 2022-02-03 and the latest 2026-07-10.
Taysha Gene Therapies, Inc. (TSHA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-02-02 | P, purchase reported on Form 4 | 10,000 | $80.1K | 2022-02-03 |
| 2023-05-16 | P, purchase reported on Form 4 | 5,000 | $3.4K | 2023-05-18 |
| 2025-08-21 | S, sale reported on Form 4 | 57,054 | $162.6K | 2025-08-22 |
| 2025-09-10 | S, sale reported on Form 4 | 200,000 | $646.0K | 2025-09-12 |
| 2025-11-28 | S, sale reported on Form 4 | 110,125 | $523.1K | 2025-12-01 |
| 2025-12-01 | S, sale reported on Form 4 | 260,047 | $1.2M | 2025-12-01 |
| 2026-01-12 | S, sale reported on Form 4 | 200,000 | $942.0K | 2026-01-14 |
| 2026-01-23 | S, sale reported on Form 4 | 89,132 | $423.4K | 2026-01-27 |
| 2026-01-26 | S, sale reported on Form 4 | 26,918 | $124.1K | 2026-01-27 |
| 2026-04-10 | S, sale reported on Form 4 | 200,000 | $892.0K | 2026-04-13 |
| 2026-07-10 | S, sale reported on Form 4 | 200,000 | $1.2M | 2026-07-10 |
Solid Biosciences Inc. (SLDB)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1665124) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms